xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas
This is an exciting experimental treatment for brain tumors with the H3K27M mutation. This is usually found in children with DIPG, and people with midline gliomas - especially of the thalamus. There are clinical trials open for it, but if you do not qualify for the trials, you may be able to get it outside of the trial. There is no cost for the expanded access program because we - the Musella Foundation - along with the other organizations mentioned in the press release - funded it with a $1 million grant! Early results presented at the last Society of Neuro-oncology meeting looked good with a few impressive responses, which is rarely, if ever seen in tumors with this mutation.
Disclosure: I have a small ownership interest in xCures.
Posted on: 03/12/2019
Click HERE to return to brain tumor news headlines